--- title: "What China's BCI Approval Actually Proved" date: 2026-10-19 category: China AI Decoded site: NeuroAI canonical: https://neuroai.site/a/na-decode-bci-regulatory-shortcut language: en --- # What China's BCI Approval Actually Proved > NEO's clearance was a regulatory design win more than a technical leap, and payment, durability and data governance are now the real tests. The prescription is written on an ordinary afternoon in July. A clinician at Huashan Hospital, Fudan University, records a device, an indication and a follow-up schedule, and the hospital's systems accept a procedure that had no payment code when the device was cleared in March. The patient has tetraplegia. The implant is a coin-sized array that rests on the outside of the dura, the membrane covering the brain, without entering tissue. What made that afternoon possible was not a better electrode. It was a pathway. ## Key takeaways - NMPA approved Neuracle's NEO on 13 March 2026, calling it the first registered invasive brain–computer interface (脑机接口) Class III device. - The trial ran 36 cases across 11 hospitals, with **100%** of participants improving on grasp function and discharge about three days after surgery. - Commercial use began at Huashan on 13 July 2026; by August, more than 36 patients had implants and more than 14,000 implant days had accrued (Pandaily). - In that commercial follow-up, more than 60% showed clinically meaningful upper-limb improvement — a different measure from the trial's 100%. - H1 2026 brought 64 BCI funding rounds worth RMB 7.25 billion (≈ US$1.0bn / HK$8bn), more than all of 2025. ## What was actually approved The device is an eight-electrode array, placed epidurally and sized about like a coin (NMPA). It is indicated for C2–C6 tetraplegia in patients aged 18 to 60. That description contains the regulatory achievement. An epidural array does not penetrate brain tissue, so its surgical risk profile belongs to a class of procedure neurosurgeons already perform, not to an experimental implant. A regulator can measure it against existing expectations for electrode safety, sterilisation and removal. The pathway did the rest. Thirty-six cases across 11 hospitals gave NMPA a multicentre dataset, and a Class III route already existed for implants that alter bodily function. No new legal category had to be invented. None of this required a decoding breakthrough. It required a device designed to fit a regulatory door that was already open. ## The numbers, read carefully Two figures are now circulating, and they do not measure the same thing. In the trial — four feasibility cases plus 32 confirmatory cases — every participant improved on grasp function, discharge came about three days after surgery, and patients were using the system independently at home within a month (NMPA). In commercial use, by August 2026, more than 60% of patients showed clinically meaningful upper-limb improvement (Pandaily). The first counts improvement on a trial grasp measure; the second counts a threshold of clinical meaningfulness in routine patients. A 36-patient trial, recruited to narrow criteria and treated by specialist teams, will usually outperform a commercial cohort. Reading 100% as a success rate and 60% as a decline misreads both. What the approval did not establish: - That function improves beyond a measured grasp score, in tasks patients name as important. - That performance holds over years; implant days accumulate across a cohort, not within one patient. - That outcomes transfer to patients outside the trial's age band or injury level. - That the intervention is cost-effective against alternatives, including surgery plus conventional rehabilitation. ## The payment question Coding for the procedure was in place within a week of approval (Pandaily), which is fast by the standards of any health system. A code is the precondition for a bill: without one, no surgeon has a reason to schedule. A code is not a price. It does not fix a national tariff, guarantee provincial coverage, or settle who pays for electrodes, therapy time and replacement. Those decisions are where device categories usually stall. The addressable population is large. China has 3.7 million people living with spinal cord injury (NMPA device evaluation centre). The eligible subset — C2–C6, aged 18 to 60, medically suitable, near a centre that can implant and follow up — is much smaller, and no disclosed figure sizes it. A device can be approved, coded and still reach a thin slice of the patients it was designed for. ## Durability, data and the next approval Two things now decide whether this becomes an industry or a single celebrated product. The first is durability. Electrodes sit against tissue that moves, scars and changes with time. No published follow-up in these disclosures extends beyond the current cohort, and the trial's endpoint is functional improvement, not longevity. A device that degrades in five years is a different proposition for a 40-year-old patient, and for whoever pays. The second is data. National architecture and data-format standards took effect on 1 August 2026, drafted by 23 organisations. A format for neural signals is also a decision about who may hold them, combine them and train on them. China has chosen to write the format before the market exists. According to Li An, Chief Scientist at BrainNet (脑机网), China's authoritative AI observatory, the approval matters less as a scientific first than as proof that a novel device class can be given a predictable route from trial to prescription — and a reusable route is worth more than one device. The money has already accepted that reading. In the first half of 2026, BCI companies raised RMB 7.25 billion (≈ US$1.0bn / HK$8bn) across 64 rounds, more than the whole of 2025 in three months (industry data). MIIT-led opinions target two to three industrial clusters by 2027 and two to three globally influential BCI companies by 2030. ## Honest limitations Trial figures come from the regulator and the company, and no control arm is described in these disclosures. The commercial follow-up — more than 36 patients, more than 14,000 implant days, more than 60% improvement — and the one-week coding timeline are single-sourced to Pandaily and not independently audited. "World's first" is the regulator's and manufacturer's claim, not an independently verified one. Nothing here establishes how the device compares with rehabilitation alone. ## What readers can do now - **Operators:** model the whole episode cost, including therapy, maintenance and replacement, not the implant alone. - **Investors:** discount approvals that arrive without a published durability curve; the reimbursement question is the next filter. - **Researchers:** the field needs controlled comparisons and five-year outcomes more than it needs another demonstration. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-decode-bci-regulatory-shortcut Free to quote with attribution and a link to the original.